Twitter Facebook LinkedIn
Center for Global Research Data

Approved Research Proposals

The table provides details of approved research proposals that have signed Data Use Agreements.

Data Request IDLead InvestigatorInstitutionResearch Proposal TitleData Contributors
3244Vojtech HuserNational Library of Medicine/NIHIdentification of Research Common Data Elements in HIV/AIDS using data science methods AbbVie, Pfizer
3246Dawn FarrellInstitute of Technology Tralee​Cochrane Review: Interventions for fatigue in inflammatory bowel diseaseAbbVie
3270Mirjana Stanic BenicUniversity Hospital Centre Rijeka​The impact of biological interventions on health‐related quality of life in adults with Crohn's diseaseAbbVie, Biogen
3287Robert AlexanderTakedaIdentification of biomarkers associated with specific sleep variablesGlaxoSmithKline
3288Marc-Antoine SparfelTours Hospital MIDRA: influence of demographic and environmental factors on anti-tumor necrosis factor efficacy in rheumatoid arthritis a systematic review and meta-analysis of randomized controlled trialsAbbVie, Pfizer, UCB
3320John FrewRockefeller UniversityAnalysis of Outcome Measures in Hidradenitis SuppurativaAbbVie
3321Ewa OlechIQVIA Study of entry variables to optimize lupus trial designGlaxoSmithKline
3328Klaus GottliebEli Lilly USAMapping of components of the complete blood count and comprehensive metabolic profile to disease-specific clinical and endoscopy endpoints in phase 2 and 3 clinical trials of ulcerative colitis and Crohn’s diseaseTakeda
3361Gustav NilsonneKarolinska InstitutetDistribution of interleukin -6 in human plasma implications for statistical modelling and meta-analysis AbbVie, GlaxoSmithKline
3369 Michael Ward
NIH Predicting Treatment Response to Tumor Necrosis Factor Inhibitors in Patients with Ankylosing SpondylitisAbbVie, Pfizer
3762Lin WangJohns Hopkins HospitalThe relative efficacy and safety of apalutamide, enzalutamide, abiraterone, and darolutamide for nonmetastatic castration-resistant prostate cancer
Pfizer, Project Data Sphere
3876Changyu ShenBeth Israel Deaconess Medical CenterRisk and Benefit Stratification of Treatment Effects in Patients with Atrial Fibrillation Boehringer Ingelheim, Daiichi Sankyo
4036Akira KimataUniversity of TsukubaOptimal interruption time of dabigatran per OS to Ablation (O-A time) in patients with atrial fibrillation Integrated analysis of 2 randomized controlled clinical trialsBoehringer Ingelheim
4037Karl PeaceGeorgia Southern UniversityAssessment of Matching Methods for Causal Analysis
Boehringer Ingelheim
4039Claire DaienCHU lapeyronie The most appropriate conventional DMARD to combine with tofacitinib in Rheumatoid Arthritis post hoc analysis of ORAL sync study Pfizer
4041Vivek RudrapatnaUniversity of California, San FranciscoEnhancing inference from real-world data using externally-derived missing data models: a pilot study of Ulcerative ColitisAbbVie, Johnson & Johnson, Takeda
4043Janneke van der WoudeErasmus Medical Center Effect of treatment on lipid profiles in patients with inflammatory bowel disease a systematic review and meta-analysis Pfizer
4047Miriam Oron
Skintelligence ltd.Test the prospects of expending the Skintelligence algorithm for predicting response to treatment with Alefacept and Ustekinumab in psoriatic patients affected with type I diabetesImmPort
4048, 4329Shomron Ben-HorinSun Yatsen 1st affiliated HospitalEfficacy of biologic drugs in short-duration versus long-duration inflammatory bowel diseaseAbbVie, Biogen, Johnson & Johnson, Takeda, UCB
4112Florian NaudetCHU RennesTolerability of duloxetine in the elderly and in adults: a systematic review and individual patient data meta-analysis of randomized controlled trials versus placeboAbbVie, Lilly, Lundbeck, Pfizer, Takeda
4113Lesley InkerTufts Medical CenterChronic Kidney Disease Epidemiology – Clinical Trials Consortium (CKD-EPI CT)GlaxoSmithKline, Takeda
4115Amir MahabadiUniversity Hospital Essen, West German Heart and Vascular CenterImpact of statin therapy on coronary artery calcification volume and density - A meta-analysis of randomized controlled trialsPfizer
4116 Sharon StraussSt. Michael’s HospitalComparative safety and effectiveness of cognitive enhancers for Alzheimer's dementia a systematic review and individual patient data network meta-analysisAbbVie
4117John FrewRockefeller UniversityPredictors of Treatment Response, Adverse Events, Changes in Anaemia status and Assessment of Lesion Count Variability in Hidradenitis Suppurativa AbbVie
4118J. David SpenceWestern UniversityOn-Treatment analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial
Pfizer
4120Merryn VoyseyUniversity of Oxford The immunogenicity and sero-efficacy of pneumococcal vaccinesPfizer
4121Frederikus KlokLeiden University Medical CenterPerformance of the AF-adapted VTE-BLEED score for predicting major bleeding in patients with atrial fibrillation a post-hoc analysis of the ENGAGE-AF TIMI-48 Study Daiichi Sankyo
4275Lisa StampUniversity of OtagoSerum urate as a biomarker in gout Protocol for individual patient data analysis for OMERACT 2020
Takeda
4278Jennifer QuintImperial College London Withdrawing inhaled corticosteroid (ICS) treatment in people with COPD a real world study
Boehringer Ingelheim
4316Martin OkunFort HealthCareGeospatial and Seasonal Variation in Psoriasis Severity Analysis of Placebo Response Data from Phase 3 placebo-controlled trials in moderate-severe psoriasis AbbVie
4319Maria Alice FranzoiJules Bordet Institut
Clinical implications of body mass index and weight in metastatic breast cancer patients receiving abemaciclib. A combined individual patient level data sub-analysis of MONARCH 2 and MONARCH 3 trials
Lilly
4324Peng XieChongqing Medical UniversityComparative efficacy and tolerability of new-generation antidepressants for major depressive disorder in children and adolescents: protocol of an individual patient data meta-analysGlaxoSmithKline, Lilly, Pfizer
4326John MarkmanUniversity of Rochester Phenotypic Characterization of Chronic Neuropathic Pain Following Post-Traumatic and Post-Surgical InjuryPfizer
4327Michael SzarekSUNY Downstate Medical CenterAnalysis of Total Events and Hospitalizations in the SPARCL Study Pfizer
4330Laure GossecSorbonne UniversitéDomains of health important for Rheumatoid Arthritis patients can be assessed separately: Reliability and Responsiveness of the Rheumatoid Arthritis Impact of Disease Score - 7 items (RAID.7i)Pfizer
4352Stefano BarcoUniversity Medical Center MainzDifferential effects of long-term treatment with warfarin vs. edoxaban on blood count parameters. A parallel posthoc analysis of the Hokusai VTE and Engage AF-TIMI-48 trialsDaiichi Sankyo
4540Chris GaleUniversity of LeedsEfficacy and safety of edoxaban versus warfarin in patients with atrial fibrillation and frailty insights from the ENGAGE AF-TIMI 48 trialDaiichi Sankyo
4541C Elizabeth CaldonGarvan Institute of Medical ResearchTherapeutic targeting of dual CDK4/6 inhibitor and endocrine resistant breast cancerPfizer
4913Susan HalabiDuke University Surrogate Endpoints of Overall Survival in Non-Metastatic Renal Clear Cell Carcinoma Pfizer, Project Data Sphere
4915Rachel TomkoMedical University of South CarolinaPredicting Individuals' Probability of Response to Smoking Cessation Pharmacotherapy Pfizer
4918Nina HilkensRadboudmc NijmegenAssociation between blood pressure, blood pressure variability and the risk of post-stroke dementiaBoehringer Ingelheim
4919Hendrik Jan GuchelaarLeiden University Medical Center (LUMC)Effect of digoxin on survival outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitorsPfizer
4920Gustavo TureckiDouglas Mental Health University InstitutePredicting Treatment Efficacy in Individuals with Major Depression -- Deep Neural Networks for Physiological Patient Parameters
Pfizer
4921Tim BrümmendorfUniversity Hospital AachenEntropy - based Biomarkers for individualized response on Bosutinib treatment in chronic phase CMLPfizer
4922, 3274Diane van der WoudeLeiden University Medical Center​Effect of rheumatoid factor and anticitrullinated peptide antibody on the efficacy of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritisAbbVie, Pfizer
4926Eva-Maria GamperMedical University InnsbruckComparison of the EORTC QLU-C10D with generic utility instruments and development of a comprehensive manual for its useBoehringer Ingelheim
4931Siddharth SinghUniversity of California, San DiegoEarly changes in inflammatory biomarkers and long-term outcomes in patients with IBD: A pooled post-hoc analyses of clinical trialsAbbVie, Takeda
4933Hongxia WangShanghai Jiao Tong University School of Medicine Novel predictive biomarker for therapeutic sensitivity of CKD4/6 inhibitor in breast cancer patients Pfizer
4949, 3190Vivek RudrapatnaUniversity of California San FranciscoEfficacy of Crohn’s Disease Treatment Stratified by Disease PhenotypeAbbVie, Biogen, Johnson & Johnson, Takeda, UCB
4950John “Devin” PeipertNorthwestern University Justification of PROMIS (FACIT) Fatigue Short Form 10a scale for FDA Drug Development ToolQualification in Rheumatoid Arthritis AbbVie
5073Philip RobinsonUniversity of QueenslandAssessment of treatment outcome using ASAS40 with etanercept in non-radiographic axSpA by baseline CRP - a re-analysis of trial dataPfizer
5074Sebastian ZundlerUniversity Hospital ErlangenEvaluation of the relationship between vedolizumab peripheral blood serum level at week 6 and binary clinical outcomes at week 10/14 - a meta-analysisTakeda
5079Maureen DubreuilBoston UniversityClinical and MRI predictors of Clinical Response in Axial SpondyloarthritisAbbVie
5080Joel SkaistisBeaumont Health Benefit of Anticoagulation in Cryptogenic Stroke According to Biomarker LevelBoehringer Ingelheim
5086Junko TakeshitaUniversity of PennsylvaniaA Systematic Review to Describe the Demographic Diversity of Dermatologic Clinical Trial Participants for Common Dermatologic DiseasesAbbVie, Lilly, Regeneron
5095Mathilde NijkeuterUniversity Medical Center UtrechtAssessing bleeding risk in patients with cancer-associated thrombosis Daiichi Sankyo
5096Joo Sang LeeSamsung Medical Center, South KoreaHarnessing genetic interactions to advance precision cancer medicineTempus Labs
5098Christopher BaethgeUniversity of Cologne Medical SchoolDose-response relationships in antidepressant pharmacotherapy of depressive disorders with (S)SNRI: a systematic review and meta-analysisLilly
5099Jorge HernandoVall d ́Hebron University Hospital Impact of gender on multikinase inhibitors (MKIs) toxicity in patients (pts) with advanced pancreatic and gastrointestinal neuroendocrine tumors (NETs)Pfizer
5163Susan BatesColumbia University Medical CenterAssessing the tumor growth and decay rates in patients with pancreatic cancer treated with Gemcitabine/Abraxane: Comparing real world data with clinical trial dataCelgene Corporation
5165Byeongzu GhangJeju National University HospitalReanalysis of CARES study to investigate the incidence of cardiovascular events and death after initiation and discontinuation of allopurinol and febuxostat
Takeda
5166Thomas MetkusJohns Hopkins University School of Medicine Severe sepsis in the cardiac intensive care unit: management strategies and outcomesLilly
5207Fasihul KhanUniversity of NottinghamA systematic review and individual patient data meta-analysis of physiological biomarkers in idiopathic pulmonary fibrosisBioLINCC, Boehringer Ingelheim, Johnson & Johnson, Roche
5209Bruce PerkinsUniversity of TorontoTRIAL-INFORMED DKA MITIGATION EDUCATIONAL TOOLBoehringer Ingelheim
5276Yan LuoKyoto UniversityPredicting the Treatment Response of Certolizumab for Individual Patients with Rheumatoid Arthritis: An Individual Participant Data Meta-Analysis UCB
5289, 5323Ashley HopkinsFlinders UniversityPredictors of therapeutic and adverse effects of medicines used in the treatment of breast cancerBoehringer Ingelheim, Lilly, Pfizer, Roche
5290Ashley HopkinsFlinders UniversityPredictors of therapeutic and adverse effects of medicines used in the treatment of gastrointestinal cancersBoehringer Ingelheim, GlaxoSmithKline, Lilly, Roche
5291Sarah NevittUniversity of LiverpoolAntiepileptic drug monotherapy for epilepsy: an updated Cochrane review and individual participant data network meta-analysisUCB
5292Désirée van der HeijdeLeiden University Medical CenterMeasurement properties of the instruments used in the outcome assessment of axial spondyloarthritisUCB
5294Daniel CaldeiraUniversity of Lisbon/CCUL The clinical impact of dabigratran in patients with non-valvular atrial fibrillation who had a fall or head injury: a retrospective analysis of RE-LY Boehringer Ingelheim
5324, 5325Daniel GoldenholzBeth Israel Deaconess Medical Center Retrospective analysis of placebo arm data in clinical epilepsy trialsGlaxoSmithKline, UCB
5330Laura BonnettUniversity of LiverpoolModelling seizure rates rather than time to an event within clinical trials of antiepileptic drugsUCB
5352Elena MyasoedovaMayo ClinicIndividualized Prediction of Treatment Response to Methotrexate in Patients with Rheumatoid Arthritis: A Machine Learning Approach
Roche, UCB
5435Matthew GilbertUniversity of VermontEffect of Albiglutide on Cardiovascular Outcomes in Older Adults with Type 2 Diabetes: a Post Hoc Analysis of a Randomized Controlled TrialGlaxoSmithKline
5436Adrian WaggUniversity of AlbertaA pooled analysis of the efficacy and tolerability of tolterodine for the treatment of Overactive Bladder (OAB) in patients over the age of 65 years of agePfizer
5456Jane LarkindaleCritical Path Institute Validation of a Model-based Clinical Trial Simulation Tool to Optimize Clinical Trial Design of Studies to Investigate Efficacy of Potential Therapies for Duchenne Muscular Dystrophy CureDuchenne
5483David McAllisterUniversity of GlasgowAssessing heterogeneity in relative treatment efficacy by age, sex and comorbidity.Boehringer Ingelheim, Lilly, Roche, Takeda, UCB
5484Stefan LeuchtTechnical University of MunichIndividual-patient-data (IPD) meta-analysis of the efficacy of clozapine versus second-generation antipsychotic drugs in patients with treatment-resistant schizophreniaPfizer
5567Neeraj NarulaMcMaster UniversityImpact of Ulcer Size and Extent of Inflammation On Ability To Achieve Endoscopic Healing In Crohn’s Disease: An EXTEND Post-Hoc AnalysisAbbVie
5812Yougen WuThe Fifth People's Hospital of Shanghai, Fudan UniversityDevelopment and validation of nomograms for predicting efficacy and toxicity in cancer patients treated with immune checkpoint inhibitorsRoche
5813Phillip GarfinSeattle Genetics Inc.Effectiveness of cytotoxic chemotherapy for the treatment metastatic breast cancer subtypesRoche
5852Marliese AlexanderPeter MacCallum Cancer Centre Infective outcomes in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: an individual patient data meta-analysisRoche
5853Florian NaudetCHU RennesData-sharing and re-analysis for main studies assessed by the European Medicines Agency - a cross-sectional study on European Public Assessment ReportsAbbVie
5869Alexandra FreemanUniversity of CambridgeMeta-analysis of the adverse effects of trastuzumab in women with breast cancer Roche
5871Nobuhisa KanaharaChiba University Center for Forensic Mental HealthDetermination of dopamine supersensitivity psychosis in randomized controlled studies of long-acting injectable vs oral agents of the same atypical antipsychotic in schizophrenia subjectsLilly
5872Yaw NyameUniversity of Washington Medical CenterRepresentation of Low-Grade Prostate Cancer in Metastatic Prostate Cancer TrialsPfizer
5880Benjamin SchneiderIowa State UniversityOptimal Scheduling of First-Line Therapeutics in Non-Small Cell Lung CancerLilly, Roche
5894Takashi SozuTokyo University of ScienceMatrix Decomposition in Meta-Analysis for Extraction of Adverse Event Pattern and Patient-Level Safety ProfileLilly
5897John PeipertNorthwestern UniversityJustification of PROMIS (FACIT) Fatigue Short Form 10a scale for FDA Drug Development Tool Qualification in Rheumatoid ArthritisPfizer
5901Junhao HuChinese Academy of Science Vessel pericytes NO-sGC signaling in COVID-19Hannover Medical School
5902Thrasyvoulos TzellosNorland University HospitalDevelopment and validation of a IHS4 dichotomous outcome for assessing anti-inflammatory treatment efficacy for the treatment of hidradenitis suppurativaAbbVie
5904Saskia MiddeldorpAmsterdam UMCHokusai post VTE study: long-term outcome after heparin plus edoxaban versus heparin plus vitamin K antagonists for acute deep vein thrombosis and pulmonary embolismDaiichi Sankyo
5921Paul Schulz University of Texas Health Science CenterIdentification of biomarkers associated with Alzheimer’s disease progression that correlate with responses to medicationsLilly
5924Iris SommerUniversity Medical Center GroningenMeta-analysis of efficacy of cholinesterase inhibitors on individual neuropsychiatric symptoms in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodiesAbbVie, GlaxoSmithKline, Johnson & Johnson
5925Min Hwan KimYonsei University College of MedicineAnalysis of neutrophil to lymphocyte ratio (NLR) in ER+ breast cancer patients to predict palbociclib clinical responsePfizer
5930Youssef ZeidanAmerican University of Beirut Medical CenterEvaluation of Radiotherapy Boost in Women with HER-2 positive Breast CancerRoche
5931Youssef ZeidanAmerican University of Beirut Medical CenterEvaluation of Radiotherapy in Triple Negative Breast Cancer: Analysis of the BEATRICE trial Roche
5932Youssef ZeidanAmerican University of Beirut Medical CenterEvaluation of Radiotherapy after Complete Response to Neoadjuvant Chemotherapy in HER-2 Positive Breast Cancer Patients Roche
5933, 5208Ahmad AbuhelwaUniversity of South AustraliaPredictors of exposure, therapeutic and adverse effects of certolizumab pegol and baricitinib used in the treatment of rheumatoid arthritisLilly, Roche, UCB
5935Jian-Guo ZhouThe Second Affiliated Hospital of Zunyi Medical UniversityLongitudinal peripheral blood markers as dynamic predictors to identify efficacy and safety of patients treated with immune checkpoint inhibitors (ICIs)Roche
5940Aziz MezliniMassachusetts General HospitalA novel statistical approach to detect the efficacy of drugs that have heterogeneous treatment effectsAbbVie, Boehringer Ingelheim, GlaxoSmithKline, Johnson & Johnson, Lundbeck, Roche, Takeda, UCB
5944Pietro SpitaliLeiden University Medical CenterPrediction of disease progression in Duchenne muscular dystrophyCureDuchenne
5945Neeraj NarulaMcMaster UniversityPredictors of Mucosal Healing in Ulcerative Colitis: A Post-hoc Analysis of VARSITYTakeda
5948Georgia SalantiUniversity of BernMaking real world predictions for clinical outcomes in Relapsing-Remitting Multiple SclerosisBiogen
5950Shirley WangBrigham and Women's HospitalUnderstanding effectiveness of new drugs in older adults shortly after market entryBoehringer Ingelheim
5951, 4543Mathilde NijkeuterUMC UtrechtIndividualized prediction of recurrence risk reduction and risk of bleeding with extended anticoagulation in patients with venous thromboembolismBoehringer Ingelheim, Daiichi Sankyo
5959John DennisUniversity of Exeter Medical SchoolStratification of SGLT2 inhibitor glucose lowering therapy in Type 2 diabetesBoehringer Ingelheim, Takeda
5960Matt LinnikEli Lilly & Co.Covid-19 Pulmonary Gene Expression Analysis Hannover Medical School
5963Elyse KatzUSSAMMDAA secondary Data-Analysis to determine treatment effectiveness in Post-Traumatic Stress DisorderLilly
5974Robert SchoeversUniversity of GroningenPrescriber effects on outcome of psychopharmacological treatment of Major Depressive Disorder (MDD)Lilly
5981Simon DagenaisVertex PharmaceuticalsIdentifying and quantifying predictors of disease progression in common measures of physical function among boys with Duchenne Muscular Dystrophy (DMD)CureDuchenne, Lilly
5982Matthew BakerStanford UniversityInvestigating the effects of rituximab on specific cell subsets and cytokine levels in systemic lupus erythematosus patients and constructing a prediction model of treatment responseRoche
5984David BakerQueen Mary University of LondonExploring possibilities to improve the riskbenefit balance through anlaysis of the ocrelizumab phase II extension studyRoche
5985, 5327Jose Antonio Pereira da SilvaUniversidade de Coimbra, PortugalLong-term predictive value of patient global assessment regarding radiographic damage and physical function in patients with Rheumatoid Arthritis: individual patient data meta-analysisAbbVie, Pfizer, Roche, UCB
5988Elad SharonNational Cancer InstituteThe Role of Targeted Agents and Their Effects on Lymphocytes and Patient OutcomesRoche
5989Jane LarkindaleCritical Path InstituteSharing of Progressive Supranuclear Palsy (PSP) data with the Rare Disease Cures Accelerator - Data and Analytics Platform for Analysis of Outcome Measures and Other PurposesAbbVie
5990Yan LuoKyoto UniversityPredicting the Treatment Response of Biologics for Individual Patients with Rheumatoid Arthritis: An Individual Participant Data Meta-AnalysisAbbVie, Roche
6003Andrea QuattroneMagna Graecia University of CatanzaroEvaluation of disease progression rate in progressive supranuclear palsy using MRI biomarkers: new implications for clinical trialsAbbVie
6004Lily LimUniversity of ManitobaIdentifying Trajectories of Disease Activity States in Juvenile Idiopathic Arthritis (JIA) Early After Treatment: Shortening Time to Decision to Change TreatmentRoche
6006Nicholas WhiteMahidol UniversityA Multiple-Dose Study to Assess the Effects of Azithromycin plus Chloroquine on Electrocardiograms in Healthy Subjects - COVID-19Pfizer
6007Judith GoldsteinJohns Hopkins School of MedicineNational Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) Calibrations for Low Vision Patients with age-related macular degeneration (AMD)Roche
6008David HsiehUniversity of Texas Southwestern Medical CenterPatterns of outcomes and the relevance surrogate endpoints in patients treated with immune checkpoint inhibitors.Roche
6024Cosima LocherUniversity Hospital ZurichPredictors of placebo response in opioid trials for patients with Chronic Primary Pain - An Individual-Patient Data (IPD) Meta-AnalysisAbbVie
6041Neeraj NarulaHamilton Health SciencesHistologic Predictors of Endoscopic Healing in Crohn's DiseaseAbbVie
6055Florian NaudetCHU RennesInferential reproducibility of therapeutic research: a registered report for a cross-sectional study of RCTs available on major data-sharing platformsAbbVie, BioLINCC, Boehringer Ingelheim, ImmPort, Lilly, Pfizer, Project Data Sphere, Roche, Takeda, UCB
6062Alex MeiselUniversity Hospital ZurichNeutrophils, Neutrophil-to-Lymphocyte Ratio (NLR) and Neutropenia as Predictors of Treatment Efficacy of Atezolizumab Monotherapy and Atezolizumab-Chemotherapy-CombinationsRoche
6064Neeraj NarulaHamilton Health SciencesComparative Effectiveness of Vedolizumab vs. Infliximab in Ulcerative ColitisJohnson & Johnson, Takeda
6068Youssef ZeidanAmerican University of Beirut Medical CenterEvaluation of Cardiotoxicity in HER-2 Positive Breast Cancer Patients Treated with Radiation Therapy and TrastuzumabyRoche
6104Pratik SinhaWashington UniversityHeterogeneous treatment effects in molecular phenotypes of sepsisLilly
6117, 5895Ashley HopkinsFlinders UniversityPredictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancersRoche
6118Roxana MehranIcahn School of Medicine at Mount SinaiAntithrombotic therapy in patients with atrial fibrillation after percutaneous coronary intervention: a systematic review and individual patient data network meta-analysis.Boehringer Ingelheim, Daiichi Sankyo
6464Michael WieseUniversity of South AustraliaIndividualisation of gout flare prophylaxis when initiating urate-lowering therapyTakeda
6477Tobias PolakErasmus Medical CenterTositumomab: statistical modeling of expanded access programs and conventional trialsGlaxoSmithKline
6482Andreas MonschUniversity of BaselAnalyses of available cognitive data from 200 healthy, German-speaking individuals to be used to examine potential patientsTakeda
6487Feng SunPeking UniversityAn individual participant data meta-analysis to evaluate a new category of hypoglycemic drugs (DPP-4Is) on type 2 diabetes mellitus patient sub-groupsBoehringer Ingelheim, Takeda
6488Feng SunPeking UniversityAn individual participant data meta-analysis to evaluate a new category of hypoglycemic drugs (SGLT-2Is) on type 2 diabetes mellitus patient sub-groupsBoehringer Ingelheim, Johnson & Johnson
6489Line UhrenholtAalborg University HospitalTapering strategies of biological and targeted synthetic disease-modifying antirheumatic drugs for patients with inflammatory arthritis: a systematic review of randomised controlled trialsAbbVie
6494Maria Alice FranzoiJules Bordet InstituteImplications of body mass index on the biological and clinical effects of endocrine therapy and abemaciclib in the neoadjuvant settingLilly
6495, 5485Günter HöglingerHanover Medical SchoolApplication of improved statistical methodologies for clinical trials in Progressive Supranuclear PalsyAbbVie
6496Neeraj NarulaHamilton Health SciencesEndoscopic Disease Severity and Patient Reported Outcomes in Crohn’s DiseaseAbbVie, Johnson & Johnson
6498Timo UphausUniversity Medical Center MainzIdentifying patients with unknown stroke etiology who may benefit from a blood thining medication with Dabigatran by a clinically based scoring systemBoehringer Ingelheim
6515Leire LeacheNavarre Health ServiceCochrane Systematic Review – Pharmacotherapy for hypertension induced left ventricular hypertrophyBoehringer Ingelheim
6521Ethan AltUniversity of North Carolina at Chapel HillBayesian probability of success for multivariate generalized linear modelsBiogen
6532Odelia CooperCedars-Sinai Medical CenterA study of how growth hormone treatment affects health outcomes in patients with noncancerous craniopharyngioma tumorsLilly
6534Diego TosiInstitut du Cancer de MontpellierAnalysis of breast cancer molecular adaptation to drugs in order to predict relapse after curative treatmentLilly
6541Dipak KotechaUniversity of BirminghamBig data and meta-analytic approaches for better phenotyping in atrial fibrillation and heart failureBoehringer Ingelheim
6543Andreas MeidHeidelberg University HospitalReproducible Machine Learning (ML) for Tumor Growth Inhibition (TGI) - can ML methods support the validity of conventional TGI metrics?Roche
6544Angela WuUniversity of OxfordInvestigating the association between smoking cessation and mental health in people with and without psychiatric disordersPfizer
6550James BrorsonThe University of ChicagoExamination of survivor functions from SOCRATES and THALES trials for kinetics of stroke recurrenceAstraZeneca
6601Dan TurnerShaare Zedek Medical CenterAdaptation and validation of the Mucosal Inflammation Non-invasive (MINI) Index for Crohn's disease in adults using the SERENE clinical trial dataAbbVie
6641Anna FeeneyMassachusetts General HospitalAntidepressants in children and adolescents with Major Depressive Disorder and the influence of placebo response: a meta-analysisPfizer
6642Neeraj NarulaHamilton Health SciencesModified Multiplier SES-CD (MM-SES-CD) on Predicting Endoscopic Remission in Crohn’s DiseaseAbbVie, Johnson & Johnson, Takeda
6686Neeraj NarulaHamilton Health SciencesExtended Validation of an Ulcerative Colitis Vedolizumab Decision Support ToolTakeda
6710Gus SlotmanInspira Health NetworkIdentifying Patients in the PROWESS SHOCK Clinical Trial Among Whom Drotrecogin Alfa (DrottAA) Reduced MortalityLilly
6712Yeon-Mok OhAsan Medical CenterDevelopment and validation of a prediction model for the indication of inhaled corticosteroid (ICS) in patients with chronic obstructive pulmonary disease (COPD)GlaxoSmithKline
6732Yung-Chuan HuangFu Jen Catholic University HospitalDecision Tree Model for Dose Selection of Dabigatran in Non-valvular Atrial Fibrillation PatientsBoehringer Ingelheim
6734Andreas Suhrbier QIMR Berghofer Medical Research instituteThe K18 mouse model recapitulates the transcriptomic response to acute COVID-19 Acute Respiratory Distress syndrome (ARDS) in humansHannover Medical School
6739Rifaquat RahmanDana Farber Cancer InstituteEvaluation of Differences in Trial and Non-Trial Patients and Leveraging of External Data for More Efficient Clinical Trial Designs in Newly Diagnosed GlioblastomaProject Data Sphere, Roche
6740Georgios PaliourasNational Centre for Scientific Research 'Demokritos' (NCSR-D)in-silico DMD: Developing computational predictive models for the progression of Duchenne Muscular DystrophyCureDuchenne
6759, 5936Zhi XiaoXiangya Hospital, Central-South UniversityRoles of neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapyRoche
6765Dan HanleyJohns Hopkins UniversityPandemic response COVID-19 Research Collaboration PlatformNYU Grossman School of Medicine, Intermountain Healthcare, Washington University School of Medicine, Bassett Research Institute, The Queen's Medical Center, Duke University, University Medical Center New Orleans
6836Alana RojewskiMedical University of South CarolinaSmoking Cessation Pharmacotherapy Efficacy in Comorbid Medical Populations: Secondary Analysis of the EAGLES Randomized Clinical TrialPfizer
7062Julien EdelineCentre Eugene MarquisPATIENT REPORTED OUTCOME (PRO) AS A PROGNOSTIC MARKER IN PATIENTS TREATED WITH TARGETED THERAPIES FOR ADVANCED HEPATOCELLULAR CARCINOMA (PRO²-HCC)Bristol Myers Squibb
7074Gregory YH LipUniversity of LiverpoolImpact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomesBoehringer Ingelheim
7075Elias ErikssonUniversity of GothenburgEfficacy of serotonin reuptake inhibitors in children and adolescentsGlaxoSmithKline, Lilly, Pfizer
7077Neeraj NarulaHamilton Health SciencesDominant Patient Reported Outcomes on Predicting Mucosal Healing in Crohn’s DiseaseAbbVie, Johnson & Johnson
7078Alberto Martini
San Raffaele UniversityRole of body mass index and Beta Blockers in metastatic urothelial carcinomaRoche
7136Shou-Ching TANGUniversity of Mississippi Medical Center (UMMC) Cancer Center and Research Inst.Validation of trastuzumab-emtansine (T-DM1) Toxicity Score to predict response to T-DM1 treatment in metastatic breast cancerRoche
7140Michael J. SorichFlinders University of South AustraliaEarly markers of clinical outcome to ipilimumab therapy for advanced melanomaBristol Myers Squibb
7145Joan BusnerSignant HealthPsychometric evaluation of Positive and Negative Syndrome Scale (PANSS) in adolescent schizophrenia trialsOtsuka
7147Carmela TartagliaUniversity of TorontoExploring the heterogeneity of cognitive profile in patients with Progressive Supranuclear Palsy (PSP) enrolled in the ABBV-8E12 trial and the relationship to brain volumesAbbVie
7158Neeraj NarulaHamilton Health SciencesPatient Reported Symptoms as Predictors of Endoscopic Improvement in Ulcerative ColitisTakeda
7159, 6634James SignorovitchAnalysis Group, Inc.Associations between steroid treatment, functional outcomes and disease milestones among non-ambulatory patients with Duchenne muscular dystrophy (DMD)CureDuchenne
7225Neeraj NarulaHamilton Health SciencesEarly vs. Delayed Response to Vedolizumab in Ulcerative ColitisTakeda
7233Gregory YH LipUniversity of LiverpoolEvaluating the outcomes and characterisation of atrial fibrillationBoehringer Ingelheim
7241Frederick ReimherrPsychiatric and Behavioral Solutions, LLCRetrospective Analysis of Emotional Symptoms in Adults with ADHD and Improvement Produced by BrexpiprazoleOtsuka
7245Manabu TakakiOkayama UniversityClinical moderators of response to nalmefene in alcohol dependence: Results from a randomized controlled trial in Japan.Otsuka
7277David CarterMMS HoldingsInternational COVID-19 Data Alliance COVID-19 WorkbenchRoche
7289Gianluca RigatelliRovigo General HospitalOutcomes of Left Main Purcutaneous Coronary Intervention across age classesDuke University